What is the origin of the Human Metapneumovirus (HMPV)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Human Metapneumovirus (HMPV) is believed to have originated from birds, specifically from avian metapneumovirus type C, approximately 200-300 years ago. The virus was first discovered in 2001 in the Netherlands by researchers at the Erasmus Medical Center in Rotterdam, who isolated it from respiratory samples of young children with respiratory tract infections 1. Despite its relatively recent discovery, serological evidence suggests that HMPV has been circulating in human populations for at least 50 years prior to its identification. Some key points about HMPV include:

  • It is a paramyxovirus closely related to RSV, causing increases in URTID and tracheobronchitis in 5%–20% of children and adults during winter 1
  • HMPV infection is commonly diagnosed by NAT, and rates range from 2.5% to 9% during the first 2 years after allogeneic HSCT 1
  • The virus underwent genetic changes that allowed it to cross the species barrier from birds to humans, adapting to efficiently infect and spread among human hosts. HMPV is now recognized as a common cause of respiratory infections worldwide, particularly in young children, the elderly, and immunocompromised individuals, causing symptoms similar to those of respiratory syncytial virus (RSV) including cough, fever, nasal congestion, and sometimes more severe lower respiratory tract infections.

From the Research

Origin of Human Metapneumovirus

  • The origin of Human Metapneumovirus (HMPV) is closely related to avian metapneumovirus subtype C, suggesting a zoonotic transfer from birds to humans 2.
  • Studies have shown that HMPV has been circulating in humans for at least 50 years, with serological evidence indicating human infection since 1958 or earlier 3.
  • The virus is believed to have evolved from avian metapneumovirus subtype C (AMPV-C) following zoonotic transfer, with AMPV-C being more closely related to HMPV than to any other AMPV subgroup 2.

Global Distribution and Prevalence

  • HMPV has been isolated from individuals with acute respiratory tract infections (ARTIs) in virtually every continent, indicating a global distribution 3.
  • The virus is a common pathogen that can cause both upper and lower respiratory tract infections, particularly in children, elderly adults, and immunocompromised hosts 3, 4, 5, 6.
  • HMPV is estimated to be responsible for about 5% to 10% of hospitalizations of children suffering from acute respiratory tract infections 5.

Epidemiology and Transmission

  • HMPV has a seasonal variation, circulating in late winter to early spring in temperate climates and late spring and summer in tropical regions 3.
  • The virus can cause severe bronchiolitis and pneumonia in children, and its symptoms are indistinguishable from those caused by human respiratory syncytial virus 5.
  • Initial infection with HMPV usually occurs during early childhood, but re-infections are common throughout life 5, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Human metapneumovirus.

Seminars in respiratory and critical care medicine, 2011

Research

Human metapneumovirus: review of an important respiratory pathogen.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.